TPG to invest in Chinese pharmaceutical firm - WSJ
NEW YORK, Oct 24 (Reuters) - Private equity firm TPG is investing in pharmaceutical-research outsourcing company Shanghai ChemPartner, The Wall Street Journal reported on its Web site on Wednesday, citing unnamed sources.
TPG, formerly known as Texas Pacific Group, will also invest in ChemPartner's sister company ChemExplorer, which works mostly for Eli Lilly & Co. (LLY.N), since it is taking a minority stake in ShangPharma, the holding company of both, the Journal reported.
The percentage and value of the stake are unclear, the Journal reported, but it will be greater than $30 million.
ChemPartner has been approached by others interested in investing about $30 million to $50 million for around 20 percent to 25 percent of the company, according to the Journal.
TPG could not be immediately reached for comment.










